In addition to this, key anti-EGFR+ tumor effects mediated by monoclonal antibodies such as cetuximab are independent of the inhibition of EGFR signaling and occur through the recruitment of cytotoxic natural killer (NK) cells, key effectors of the innate immune system which eradicate tumor cells through ADCC (23, 150). This evidence concerns the gene EGFR and neoplasm.